ArticleCureus2025
Ventriculoperitoneal Shunt and Endoscopic Third Ventriculostomy for Hydrocephalus in Adult Patients With Brain Metastases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with brain metastases and concurrent hydrocephalus warrant expedited treatment. This study evaluated survival outcomes of patients with brain metastases and hydrocephalus treated with endoscopic third ventriculostomy (ETV) or ventriculoperitoneal shunt (VPS) placement. Materials and methods: Twenty patients with brain metastases and hydrocephalus were treated with ETV or VPS over 10 years (July 18, 2013-November 20, 2023). Our findings were juxtaposed against data from 77 published controls to assess whether ETV and VPS management correlated with enhanced survival. Results: The most common primary cancer diagnoses were breast (9 [45%]) and non-small cell lung cancer (5 [25%]). Seven (35%) patients had leptomeningeal carcinomatosis. The initial procedure to treat hydrocephalus was a VPS in 13 (65%) patients; seven (35%) had an ETV first. Patients with a single brain metastatic lesion had a longer median overall survival (OS) than those with more than one metastatic site (154.5 versus 67.0 days). Our cohort had a similar median OS following the ETV/VPS procedure compared to published data (92.5 versus 91 days). In both ETV and VPS subsets, our cohort had a longer median OS than published data: 106 versus 56 days for ETV and 79 versus 56 days for VPS. Conclusions: Patients with brain metastases and hydrocephalus who underwent an ETV or VPS placement had improved survival compared to historical controls and if they had only one metastatic lesion. Interdisciplinary evaluation of patients with brain metastases by neurosurgeons as well as medical and radiation oncologists is warranted to facilitate systemic therapy after hydrocephalus relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.